LivaNova Reports Third-Quarter 2022 Results with Revenue of $252.6M

LivaNova PLC

2022-Q3 EPS reported -$1.64 revenue$746,931,000

Revenue of $252.6M decreased 0.2% reported but increased 5.2% on constant-currency basis vs prior year.
GAAP diluted loss per share of $2.01 includes non-cash goodwill impairment of ~$2.40 per share; adjusted diluted EPS was $0.58.
Michael Hutchinson named Senior Vice President, Chief Legal Officer and Company Secretary, succeeding Keyna Skeffington.
Full-year 2022 outlook unchanged; focus on core growth drivers, clinical pipeline, and cash generation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

LivaNova PLC reported the quarter ended September 30, 2022 results: revenue $252.6 million, EPS $2.01. Guidance reaffirmed.

Period: the quarter ended September 30, 2022
Revenue: $252.6 million
EPS: $2.01
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Revenue of $252.6 million for the quarter decreased 0.2 percent on a reported basis and increased 5.2 percent on a constant-currency basis, as compared to the prior-year period • U.S. GAAP diluted loss per share was $2.01, including a non-cash goodwill impairment charge of approximately $2.40 per share, and adjusted diluted earnings per share was $0.58

View on SEC.gov

Browse all earnings releases →

LivaNova PLC filing history →

Source: SEC EDGAR

accession 0001639691-22-000098

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.